Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
52
PHCRF Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
1.49%
Day range:
$0.84 - $0.84
52-week range:
$0.84 - $0.97
Dividend yield:
0%
P/E ratio:
17.36x
P/S ratio:
0.70x
P/B ratio:
0.96x
Volume:
--
Avg. volume:
--
1-year change:
-13.4%
Market cap:
$610M
Revenue:
$870.5M
EPS (TTM):
-$0.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHCRF
Healius Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
MESO
Mesoblast Ltd.
|
$23M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHCRF
Healius Ltd.
|
$0.84 | -- | $610M | 17.36x | $0.26 | 0% | 0.70x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.08 | $12.00 | $55.8M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.86 | $9.50 | $416.3M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$6.89 | $19.01 | $11.5M | -- | $0.00 | 0% | 311.32x |
|
MESO
Mesoblast Ltd.
|
$18.04 | $35.00 | $2.3B | -- | $0.00 | 0% | 126.61x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHCRF
Healius Ltd.
|
57.67% | 0.255 | -- | 0.32x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.761 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.437 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.217 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 2.583 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHCRF
Healius Ltd.
|
-- | -- | -1.04% | -2.19% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Healius Ltd. vs. Competitors
-
Which has Higher Returns PHCRF or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Healius Ltd.'s net margin of --. Healius Ltd.'s return on equity of -2.19% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHCRFHealius Ltd.-- -- $1.5B ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About PHCRF or ATHE?
Healius Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 289.61%. Given that Alterity Therapeutics Ltd. has higher upside potential than Healius Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Healius Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHCRFHealius Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is PHCRF or ATHE More Risky?
Healius Ltd. has a beta of -0.092, which suggesting that the stock is 109.21% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.065, suggesting its less volatile than the S&P 500 by 93.549%.
-
Which is a Better Dividend Stock PHCRF or ATHE?
Healius Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healius Ltd. pays 53.27% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. Healius Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHCRF or ATHE?
Healius Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Healius Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Healius Ltd.'s price-to-earnings ratio is 17.36x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healius Ltd. is 0.70x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHCRFHealius Ltd.0.70x 17.36x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns PHCRF or IMMP?
Immutep Ltd. has a net margin of -- compared to Healius Ltd.'s net margin of --. Healius Ltd.'s return on equity of -2.19% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHCRFHealius Ltd.-- -- $1.5B IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About PHCRF or IMMP?
Healius Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 232.17%. Given that Immutep Ltd. has higher upside potential than Healius Ltd., analysts believe Immutep Ltd. is more attractive than Healius Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHCRFHealius Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is PHCRF or IMMP More Risky?
Healius Ltd. has a beta of -0.092, which suggesting that the stock is 109.21% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.781%.
-
Which is a Better Dividend Stock PHCRF or IMMP?
Healius Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healius Ltd. pays 53.27% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. Healius Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHCRF or IMMP?
Healius Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Healius Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Healius Ltd.'s price-to-earnings ratio is 17.36x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healius Ltd. is 0.70x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHCRFHealius Ltd.0.70x 17.36x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns PHCRF or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Healius Ltd.'s net margin of --. Healius Ltd.'s return on equity of -2.19% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital PHCRFHealius Ltd.-- -- $1.5B KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About PHCRF or KZIA?
Healius Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 176.4%. Given that Kazia Therapeutics Ltd. has higher upside potential than Healius Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Healius Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHCRFHealius Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is PHCRF or KZIA More Risky?
Healius Ltd. has a beta of -0.092, which suggesting that the stock is 109.21% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.739, suggesting its more volatile than the S&P 500 by 73.892%.
-
Which is a Better Dividend Stock PHCRF or KZIA?
Healius Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healius Ltd. pays 53.27% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. Healius Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHCRF or KZIA?
Healius Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Healius Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Healius Ltd.'s price-to-earnings ratio is 17.36x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healius Ltd. is 0.70x versus 311.32x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHCRFHealius Ltd.0.70x 17.36x -- -- KZIAKazia Therapeutics Ltd.311.32x -- -- --
-
Which has Higher Returns PHCRF or MESO?
Mesoblast Ltd. has a net margin of -- compared to Healius Ltd.'s net margin of --. Healius Ltd.'s return on equity of -2.19% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHCRFHealius Ltd.-- -- $1.5B MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About PHCRF or MESO?
Healius Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 94.01%. Given that Mesoblast Ltd. has higher upside potential than Healius Ltd., analysts believe Mesoblast Ltd. is more attractive than Healius Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PHCRFHealius Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is PHCRF or MESO More Risky?
Healius Ltd. has a beta of -0.092, which suggesting that the stock is 109.21% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.140, suggesting its more volatile than the S&P 500 by 113.996%.
-
Which is a Better Dividend Stock PHCRF or MESO?
Healius Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healius Ltd. pays 53.27% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. Healius Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHCRF or MESO?
Healius Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Healius Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Healius Ltd.'s price-to-earnings ratio is 17.36x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healius Ltd. is 0.70x versus 126.61x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHCRFHealius Ltd.0.70x 17.36x -- -- MESOMesoblast Ltd.126.61x -- -- --
-
Which has Higher Returns PHCRF or PPCB?
has a net margin of -- compared to Healius Ltd.'s net margin of --. Healius Ltd.'s return on equity of -2.19% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHCRFHealius Ltd.-- -- $1.5B PPCB-- -$0.00 -- -
What do Analysts Say About PHCRF or PPCB?
Healius Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Healius Ltd. has higher upside potential than , analysts believe Healius Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings PHCRFHealius Ltd.0 0 0 PPCB0 0 0 -
Is PHCRF or PPCB More Risky?
Healius Ltd. has a beta of -0.092, which suggesting that the stock is 109.21% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock PHCRF or PPCB?
Healius Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healius Ltd. pays 53.27% of its earnings as a dividend. pays out -- of its earnings as a dividend. Healius Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHCRF or PPCB?
Healius Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Healius Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Healius Ltd.'s price-to-earnings ratio is 17.36x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healius Ltd. is 0.70x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHCRFHealius Ltd.0.70x 17.36x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.15% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.93% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 9.59% over the past day.
